TELIK ANNOUNCES EXPANSION OF PHASE 2 TRIAL OF TELCYTA IN
HEMATOLOGIC MALIGNANCIES
Palo Alto, CA - February 21, 2012 - Telik, Inc. (Nasdaq:
TELK) today announced that the Phase 2 investigator-led
Telcyta trial in hematologic malignancies has been expanded
to an additional investigational site, Memorial
Sloan-Kettering Cancer Center (MSKCC). Based upon the
results observed in Stage 1 of the trial, which is being
conducted at the Robert Wood Johnson University Hospital
under the direction of Joseph R. Bertino, MD of The Cancer
Institute of New Jersey, an additional 10 patients with
chemotherapy resistant multiple myeloma may be
enrolled. Additional trial investigators at MSKCC are
Sergio A. Giralt, MD and Nikoletta Lendvai, MD, PhD.
About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug
development company focused on discovering and developing
small molecule drugs to treat cancer. The company's
most advanced drug candidate is Telintra®, a modified
glutathione analog intended for the treatment of hematologic
malignancies including myelodysplastic syndrome; followed by
Telcyta®, a cancer activated prodrug for the treatment of a
variety of cancers. Telik's product candidates were
discovered using its proprietary drug discovery technology,
TRAP®, which enables the rapid and efficient discovery of
small molecule drug candidates.
Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are
trademarks or registered trademarks of Telik, Inc.
###
Contact:
Denise San Bartolome
Corporate Communications
Telik, Inc.
Tel: 650 845 7712
Email: denisesb@telik.com